Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands
- PMID: 22120195
- DOI: 10.1016/j.vaccine.2011.11.054
Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands
Abstract
Respiratory syncytial virus (RSV) infection is the most important viral cause of severe respiratory disease in infants and children worldwide and also forms a serious threat in the elderly. The development of RSV vaccine, however, has been hampered by the disastrous outcome of an earlier trial using an inactivated and parenterally administered RSV vaccine which did not confer protection but rather primed for enhanced disease upon natural infection. Mucosal administration does not seem to prime for enhanced disease, but non-replicating RSV antigen does not induce a strong mucosal immune response. We therefore investigated if mucosal immunization with inactivated RSV supplemented with innate receptor ligands, TLR9 (CpG ODN) and NOD2 (L18-MDP) through the upper or total respiratory tract is an effective and safe approach to induce RSV-specific immunity. Our data show that beta-propiolactone (BPL) inactivated RSV (BPL-RSV) supplemented with CpG ODN and L18-MDP potentiates activation of antigen-presenting cells (APC) in vitro, as demonstrated by NF-κB induction in a model APC cell line. In vivo, BPL-RSV supplemented with CpG ODN/L18-MDP ligands induces local IgA responses and augments Th1-signature IgG2a subtype responses after total respiratory tract (TRT), but less efficient after upper respiratory tract (intranasal, IN) immunization. Addition of TLR9/NOD2 ligands to the inactivated RSV also promoted affinity maturation of RSV-specific IgG antibodies and shifted T cell responses from mainly IL-5-secreting cells to predominantly IFN-γ-producing cells, indicating a Th1-skewed response. This effect was seen for both IN and TRT immunization. Finally, BPL-RSV supplemented with TLR9/NOD2 ligands significantly improved the protection efficacy against a challenge with infectious virus, without stimulating enhanced disease as evidenced by lack of eotaxin mRNA expression and eosinophil infiltration in the lung. We conclude that mucosal immunization with inactivated RSV antigen supplemented with TLR9/NOD2 ligands is a promising approach to induce effective RSV-specific immunity without priming for enhanced disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.Clin Diagn Lab Immunol. 2005 Jan;12(1):171-9. doi: 10.1128/CDLI.12.1.171-179.2005. Clin Diagn Lab Immunol. 2005. PMID: 15643003 Free PMC article.
-
Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.Vaccine. 2013 Apr 19;31(17):2169-76. doi: 10.1016/j.vaccine.2013.02.043. Epub 2013 Mar 13. Vaccine. 2013. PMID: 23499594
-
Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.PLoS One. 2013 Apr 8;8(4):e61287. doi: 10.1371/journal.pone.0061287. Print 2013. PLoS One. 2013. PMID: 23593453 Free PMC article.
-
Immunopathology of RSV infection: prospects for developing vaccines without this complication.Rev Med Virol. 2007 Jan-Feb;17(1):5-34. doi: 10.1002/rmv.518. Rev Med Virol. 2007. PMID: 17004293 Review.
-
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.
Cited by
-
Vaccines and Dementia: Part I. Non-Specific Immune Boosting with BCG: History, Ligands, and Receptors.J Alzheimers Dis. 2024;98(2):343-360. doi: 10.3233/JAD-231315. J Alzheimers Dis. 2024. PMID: 38393912 Free PMC article. Review.
-
Gamma Irradiation-Inactivated Respiratory Syncytial Virus Vaccine Provides Protection but Exacerbates Pulmonary Inflammation by Switching from Prefusion to Postfusion F Protein.Microbiol Spectr. 2023 Aug 17;11(4):e0135823. doi: 10.1128/spectrum.01358-23. Epub 2023 Jun 5. Microbiol Spectr. 2023. PMID: 37272801 Free PMC article.
-
A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection.Front Immunol. 2022 Jun 14;13:841471. doi: 10.3389/fimmu.2022.841471. eCollection 2022. Front Immunol. 2022. PMID: 35774800 Free PMC article.
-
Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection.Sci Rep. 2021 Sep 20;11(1):18641. doi: 10.1038/s41598-021-97535-6. Sci Rep. 2021. PMID: 34545126 Free PMC article.
-
Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0049121. doi: 10.1128/AAC.00491-21. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 34001511 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous